SomantiX B.V. is a Dutch biotech company focusing on the identification and development of new angiogenesis inhibitors for the treatment of solid cancers through targeting of tumor blood vessels.
Somantix’ screening platform in combination with the binder generation technologies allows validation of new therapeutic targets and development of new cancer medicines.
Hugo R. Kruyt building
Floor 8, Room O.807
3584 CH Utrecht
Phone +31 (0)30-7600976